Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDROXYSSc trial of hydroxychloroquine add-on therapy in early systemic sclerosis
2021-000230-33Phase 3Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Hydroxychloroquine add-on with Placebo add-on (2 arms). Primary endpoint: Change from baseline in CRISS at week 52. Started Aug 2021; status: active.
02
Drugs
hydroxychloroquine
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2021-000230-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000230-33.